Mylan N.V. Securities Litigation (2019)

If you purchased a significant amount of shares of Mylan N.V. (NASDAQ: MYL), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Mylan N.V.
Date Filed:December 16th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:May 9th, 2018
Class End Date:May 6th, 2019

According to the Complaint, Mylan is a Dutch company with its global headquarters located in Pennsylvania, United States. Mylan began in 1961 as a privately-owned distributor for pharmacies and doctors. In 1965, Mylan relocated to Pennsylvania and in 1973, Mylan became publicly traded. In 2015, Mylan acquired Abbott Laboratories' non-U.S. market specialties and branded generics business and became a public limited liability company in the Netherlands.

The Complaint alleges that during the Class Period, Mylan made false and/or misleading statements and/or failed to disclose that: (1) Mylan's Morgantown facility was in significant violation of the FDA's Current Good Manufacturing Practice regulations; (2) Mylan would need to engage in a massive restructuring and remediation program; (3) Mylan's North American Segment would be substantially impacted by said program, which would in turn materially impact Mylan's financial health; (3) Mylan lacked effective internal control over financial reporting; and (4) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Mylan N.V.

 
First Identified Complaint

Daniel Brody, et al. v. Mylan N.V., et al.

Date Filed:December 16th, 2019
Class Period Start:May 9th, 2018
Class Period End:May 6th, 2019
First Identified Complaint Filings
#Document TitleFiling Date